3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
2
Gastrointestinal
2
Sarcoma
1
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
CNS
1
Conditions
Vascular Diseases
1
Paraproteinemias
1
Neoplasms, Plasma Cell
1
Neoplasms by Histologic Type
1
Neoplasms
1
Multiple Myeloma
1
Lymphoproliferative Disorders
1
Lymphoma
1
Lymphatic Diseases
1
Immunoproliferative Disorders
1
Hemorrhagic Disorders
1
Hematologic Diseases
1
Cardiovascular Diseases
1
Blood Protein Disorders
1
Interventions
Dexamethasone
139
Lenalidomide
75
Cyclophosphamide
73
Bortezomib
73
Calcium Dobesilate
57
fludarabine
49
pomalidomide
43
daratumumab
39
fludarabine phosphate
34
carfilzomib
33
Melphalan
29
dexamethasone acetate
24
dexamethasone 21-phosphate
24
auricularum
22
Filgrastim
18
Whole-Body Irradiation
15
Biopsy
14
ixazomib
13
isatuximab
13
Magnetic Resonance Spectroscopy
13
Granulocyte Colony-Stimulating Factor
13
Vorinostat
12
Tacrolimus
12
Specimen Handling
12
Sirolimus
12
Peripheral Blood Stem Cell Transplantation
12
venetoclax
11
belantamab mafodotin
11
Rituximab
11
Panobinostat
10
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
ficlatuzumab
×
Plasma cell
×
Clear all
NCT00725634
2014-01-27
P05538
AVEO Pharmaceuticals, Inc.
Phase 1
Completed
41 enrolled